| http://www.w3.org/ns/prov#value | - ?? our collaborators may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, a change in business strategy, a change of control or other reasons; ?? our contracts for collaborative arrangements may expire; ?? our partners may choose to pursue alternative technologies, including those of our competitors; ?? we may have disputes with a partner that co
|
